X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Escozine (Caribbean Blue Scorpion Peptides Derived Extract), a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, is being researched as a treatment of various indications, including COVID-19 and cancer.
Lead Product(s): Caribbean Blue Scorpion Peptides Derived Extract
Therapeutic Area: Infections and Infectious Diseases Product Name: Escozine
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
The results showed an increase of COX-2 inhibition in the polarized sample when compared to the non-polarized sample, where the inhibition was 257.67% higher than the non-polarized sample of ibuprofen.
Lead Product(s): Ibuprofen
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Physicians observed that patients who originally had strong adverse reactions to COVID-19 vaccines and who were given Escozine®, experienced significantly lessened side effects.
Lead Product(s): Caribbean Blue Scorpion Ptides Derived Extract
Therapeutic Area: Infections and Infectious Diseases Product Name: Escozine
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2021
Details:
The response included: recognition from the FDA on the therapeutic effects of Escozine®, validation of the Company’s clinical trial as an informal proof-of-concept study, and laid out very specific guidelines for regulatory approval of Escozine®.
Lead Product(s): Caribbean Blue Scorpion Extract
Therapeutic Area: Infections and Infectious Diseases Product Name: Escozine
Highest Development Status: N/AProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
Medolife and The Ministry of Environment of The Dominican Republic signed an exclusive 10-year agreement with automatic renewal. The partnership grants exclusive rights for investigations, production, and distribution world-wide for a Scorpion venom to the Dominican Republic.
Lead Product(s): Scorpion venom
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: N/AProduct Type: Peptide
Partner/Sponsor/Collaborator: Ministry of Environment of The Dominican Republic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
